DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Methylene blue |
DMJAPE7
|
Moderate |
Additive hypertensive effects by the combination of Formoterol and Methylene blue. |
Acquired methaemoglobinaemia [3A93]
|
[13] |
Ivosidenib |
DM8S6T7
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Ivosidenib. |
Acute myeloid leukaemia [2A60]
|
[14] |
Midostaurin |
DMI6E0R
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[14] |
Idarubicin |
DMM0XGL
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Idarubicin. |
Acute myeloid leukaemia [2A60]
|
[14] |
Arn-509 |
DMT81LZ
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Arn-509. |
Acute myeloid leukaemia [2A60]
|
[14] |
Gilteritinib |
DMTI0ZO
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Gilteritinib. |
Acute myeloid leukaemia [2A60]
|
[14] |
Oliceridine |
DM6MDCF
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Oliceridine. |
Acute pain [MG31]
|
[14] |
Ivabradine |
DM0L594
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Ivabradine. |
Angina pectoris [BA40]
|
[14] |
Bepridil |
DM0RKS4
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Bepridil. |
Angina pectoris [BA40]
|
[14] |
Bedaquiline |
DM3906J
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[14] |
Cilostazol |
DMZMSCT
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Cilostazol. |
Arterial occlusive disease [BD40]
|
[14] |
Posaconazole |
DMUL5EW
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Posaconazole. |
Aspergillosis [1F20]
|
[14] |
Lisdexamfetamine |
DM6W8V5
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Lisdexamfetamine. |
Attention deficit hyperactivity disorder [6A05]
|
[14] |
Droxidopa |
DM5YF4M
|
Moderate |
Additive hypertensive effects by the combination of Formoterol and Droxidopa. |
Autonomic nervous system disorder [8D87]
|
[15] |
Ofloxacin |
DM0VQN3
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Ofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[14] |
Clarithromycin |
DM4M1SG
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Clarithromycin. |
Bacterial infection [1A00-1C4Z]
|
[14] |
Gemifloxacin |
DMHT34O
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Gemifloxacin. |
Bacterial infection [1A00-1C4Z]
|
[14] |
Norfloxacin |
DMIZ6W2
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Norfloxacin. |
Bacterial infection [1A00-1C4Z]
|
[14] |
Levofloxacin |
DMS60RB
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Levofloxacin. |
Bacterial infection [1A00-1C4Z]
|
[14] |
Retigabine |
DMGNYIH
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Retigabine. |
Behcet disease [4A62]
|
[14] |
Eribulin |
DM1DX4Q
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[14] |
Lapatinib |
DM3BH1Y
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Lapatinib. |
Breast cancer [2C60-2C6Y]
|
[14] |
Bosutinib |
DMTI8YE
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Bosutinib. |
Breast cancer [2C60-2C6Y]
|
[14] |
Corticotropin |
DMP9TWZ
|
Minor |
Increased risk of hypokalemia by the combination of Formoterol and Corticotropin. |
Chronic kidney disease [GB61]
|
[12] |
PF-04449913 |
DMSB068
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and PF-04449913. |
Chronic myelomonocytic leukaemia [2A40]
|
[14] |
Levomilnacipran |
DMV26S8
|
Moderate |
Additive hypertensive effects by the combination of Formoterol and Levomilnacipran. |
Chronic pain [MG30]
|
[16] |
Halothane |
DM80OZ5
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Halothane. |
Corneal disease [9A76-9A78]
|
[14] |
Sevoflurane |
DMC9O43
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Sevoflurane. |
Corneal disease [9A76-9A78]
|
[14] |
Probucol |
DMVZQ2M
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Probucol. |
Coronary atherosclerosis [BA80]
|
[14] |
Pasireotide |
DMHM7JS
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Pasireotide. |
Cushing syndrome [5A70]
|
[14] |
Osilodrostat |
DMIJC9X
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Osilodrostat. |
Cushing syndrome [5A70]
|
[14] |
Sertraline |
DM0FB1J
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Sertraline. |
Depression [6A70-6A7Z]
|
[14] |
Selegiline |
DM6034S
|
Moderate |
Additive hypertensive effects by the combination of Formoterol and Selegiline. |
Depression [6A70-6A7Z]
|
[13] |
Isocarboxazid |
DMAF1NB
|
Moderate |
Additive hypertensive effects by the combination of Formoterol and Isocarboxazid. |
Depression [6A70-6A7Z]
|
[13] |
Milnacipran |
DMBFE74
|
Moderate |
Increased risk of rapid heart rate by the combination of Formoterol and Milnacipran. |
Depression [6A70-6A7Z]
|
[16] |
Escitalopram |
DMFK9HG
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Escitalopram. |
Depression [6A70-6A7Z]
|
[14] |
Desvenlafaxine |
DMHD4PE
|
Moderate |
Increased risk of rapid heart rate by the combination of Formoterol and Desvenlafaxine. |
Depression [6A70-6A7Z]
|
[16] |
Tetrabenazine |
DMYWQ0O
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Tetrabenazine. |
Dissociative neurological symptom disorder [6B60]
|
[14] |
Deutetrabenazine |
DMUPFLI
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Deutetrabenazine. |
Dystonic disorder [8A02]
|
[14] |
Ingrezza |
DMVPLNC
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Ingrezza. |
Dystonic disorder [8A02]
|
[14] |
Solifenacin |
DMG592Q
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Solifenacin. |
Functional bladder disorder [GC50]
|
[14] |
Ketoconazole |
DMPZI3Q
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Ketoconazole. |
Fungal infection [1F29-1F2F]
|
[14] |
Sunitinib |
DMCBJSR
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Sunitinib. |
Gastrointestinal stromal tumour [2B5B]
|
[14] |
Procarbazine |
DMIK367
|
Moderate |
Additive hypertensive effects by the combination of Formoterol and Procarbazine. |
Hodgkin lymphoma [2B30]
|
[13] |
Saquinavir |
DMG814N
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Saquinavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[14] |
Lopinavir |
DMITQS0
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Lopinavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[17] |
Rilpivirine |
DMJ0QOW
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Rilpivirine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[14] |
Crizotinib |
DM4F29C
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Crizotinib. |
Lung cancer [2C25]
|
[14] |
Ceritinib |
DMB920Z
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Ceritinib. |
Lung cancer [2C25]
|
[14] |
Osimertinib |
DMRJLAT
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Osimertinib. |
Lung cancer [2C25]
|
[14] |
Selpercatinib |
DMZR15V
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Selpercatinib. |
Lung cancer [2C25]
|
[14] |
Lumefantrine |
DM29GAD
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Lumefantrine. |
Malaria [1F40-1F45]
|
[17] |
Halofantrine |
DMOMK1V
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Halofantrine. |
Malaria [1F40-1F45]
|
[14] |
Hydroxychloroquine |
DMSIVND
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Hydroxychloroquine. |
Malaria [1F40-1F45]
|
[14] |
Primaquine |
DMWQ16I
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Primaquine. |
Malaria [1F40-1F45]
|
[14] |
Inotuzumab ozogamicin |
DMAC130
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[14] |
Arsenic trioxide |
DM61TA4
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Arsenic trioxide. |
Mature B-cell lymphoma [2A85]
|
[14] |
Vemurafenib |
DM62UG5
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Vemurafenib. |
Melanoma [2C30]
|
[14] |
LGX818 |
DMNQXV8
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and LGX818. |
Melanoma [2C30]
|
[14] |
Panobinostat |
DM58WKG
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Panobinostat. |
Multiple myeloma [2A83]
|
[14] |
Siponimod |
DM2R86O
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Siponimod. |
Multiple sclerosis [8A40]
|
[14] |
Fingolimod |
DM5JVAN
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Fingolimod. |
Multiple sclerosis [8A40]
|
[14] |
Ozanimod |
DMT6AM2
|
Major |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Ozanimod. |
Multiple sclerosis [8A40]
|
[18] |
Romidepsin |
DMT5GNL
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Romidepsin. |
Mycosis fungoides [2B01]
|
[14] |
Dasatinib |
DMJV2EK
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Dasatinib. |
Myeloproliferative neoplasm [2A20]
|
[14] |
Promethazine |
DM6I5GR
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Promethazine. |
Nausea/vomiting [MD90]
|
[14] |
Entrectinib |
DMMPTLH
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Entrectinib. |
Non-small cell lung cancer [2C25]
|
[14] |
Sibutramine |
DMFJTDI
|
Moderate |
Increased risk of rapid heart rate by the combination of Formoterol and Sibutramine. |
Obesity [5B80-5B81]
|
[19] |
Levomethadyl Acetate |
DM06HG5
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Levomethadyl Acetate. |
Opioid use disorder [6C43]
|
[17] |
Lofexidine |
DM1WXA6
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Lofexidine. |
Opioid use disorder [6C43]
|
[14] |
Rucaparib |
DM9PVX8
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Rucaparib. |
Ovarian cancer [2C73]
|
[14] |
Triclabendazole |
DMPWGBR
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Triclabendazole. |
Parasitic worm infestation [1F90]
|
[14] |
Safinamide |
DM0YWJC
|
Moderate |
Additive hypertensive effects by the combination of Formoterol and Safinamide. |
Parkinsonism [8A00]
|
[13] |
Rasagiline |
DM3WKQ4
|
Moderate |
Additive hypertensive effects by the combination of Formoterol and Rasagiline. |
Parkinsonism [8A00]
|
[13] |
Pimavanserin |
DMR7IVC
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Pimavanserin. |
Parkinsonism [8A00]
|
[14] |
Macimorelin |
DMQYJIR
|
Major |
Increased risk of prolong QT interval by the combination of Formoterol and Macimorelin. |
Pituitary gland disorder [5A60-5A61]
|
[20] |
Lefamulin |
DME6G97
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Lefamulin. |
Pneumonia [CA40]
|
[14] |
Degarelix |
DM3O8QY
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Degarelix. |
Prostate cancer [2C82]
|
[14] |
ABIRATERONE |
DM8V75C
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and ABIRATERONE. |
Prostate cancer [2C82]
|
[14] |
Enzalutamide |
DMGL19D
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Enzalutamide. |
Prostate cancer [2C82]
|
[14] |
Relugolix |
DMK7IWL
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Relugolix. |
Prostate cancer [2C82]
|
[14] |
Bicalutamide |
DMZMSPF
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Bicalutamide. |
Prostate cancer [2C82]
|
[14] |
Levomepromazine |
DMIKFEL
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Levomepromazine. |
Psychotic disorder [6A20-6A25]
|
[14] |
Gatifloxacin |
DMSL679
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Gatifloxacin. |
Respiratory infection [CA07-CA4Z]
|
[14] |
Ciclesonide |
DM2NA4K
|
Minor |
Increased risk of hypokalemia by the combination of Formoterol and Ciclesonide. |
Respiratory system disease [CB40-CB7Z]
|
[12] |
Dexamethasone |
DMMWZET
|
Minor |
Increased risk of hypokalemia by the combination of Formoterol and Dexamethasone. |
Rheumatoid arthritis [FA20]
|
[12] |
Quetiapine |
DM1N62C
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Quetiapine. |
Schizophrenia [6A20]
|
[14] |
Aripiprazole |
DM3NUMH
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Aripiprazole. |
Schizophrenia [6A20]
|
[21] |
Iloperidone |
DM6AUFY
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Iloperidone. |
Schizophrenia [6A20]
|
[14] |
Paliperidone |
DM7NPJS
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Paliperidone. |
Schizophrenia [6A20]
|
[14] |
Amisulpride |
DMSJVAM
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Amisulpride. |
Schizophrenia [6A20]
|
[14] |
Asenapine |
DMSQZE2
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Asenapine. |
Schizophrenia [6A20]
|
[14] |
Pimozide |
DMW83TP
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Pimozide. |
Schizophrenia [6A20]
|
[14] |
LEE011 |
DMMX75K
|
Major |
Increased risk of prolong QT interval by the combination of Formoterol and LEE011. |
Solid tumour/cancer [2A00-2F9Z]
|
[22] |
Vandetanib |
DMRICNP
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Vandetanib. |
Solid tumour/cancer [2A00-2F9Z]
|
[14] |
Triptorelin |
DMTK4LS
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Triptorelin. |
Solid tumour/cancer [2A00-2F9Z]
|
[14] |
Doxorubicin |
DMVP5YE
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Doxorubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[14] |
Pitolisant |
DM8RFNJ
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Pitolisant. |
Somnolence [MG42]
|
[14] |
Telavancin |
DM58VQX
|
Moderate |
Increased risk of ventricular arrhythmias by the combination of Formoterol and Telavancin. |
Staphylococcal/streptococcal disease [1B5Y]
|
[14] |
Cabozantinib |
DMIYDT4
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Cabozantinib. |
Thyroid cancer [2D10]
|
[14] |
Fluticasone |
DMGCSVF
|
Minor |
Increased risk of hypokalemia by the combination of Formoterol and Fluticasone. |
Vasomotor/allergic rhinitis [CA08]
|
[12] |
Procainamide |
DMNMXR8
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Procainamide. |
Ventricular tachyarrhythmia [BC71]
|
[14] |
Flecainide |
DMSQDLE
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Flecainide. |
Ventricular tachyarrhythmia [BC71]
|
[14] |
Amiodarone |
DMUTEX3
|
Moderate |
Increased risk of prolong QT interval by the combination of Formoterol and Amiodarone. |
Ventricular tachyarrhythmia [BC71]
|
[14] |
----------- |
|
|
|
|
|